Effects of Sacubitril/Valsartan combined with Metoprolol in treatment of patients with chronic heart failure
Objective:To observe effects of Sacubitril/Valsartan combined with Metoprolol in treatment of patients with chronic heart failure(CHF).Methods:A prospective study was conducted on 80 patients with CHF admitted to the hospital from March 2021 to December 2022.According to the random number table method,they were divided into control group and observation group,40 cases in each group.Both groups were given routine treatment.On this basis,the control group was treated with Metoprolol,while the observation group was treated with Sacubitril/Valsartan on the basis of that of the control group.Both groups were treated for 3 months.The clinical efficacy,the cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular mass index(LVMI)]levels,the serological indexes[N-terminal pro-brain natriuretic peptide(NT-proBNP),cardiac troponin I(cTnI)]levels,the inflammatory indexes[high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)]levels,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of the observation group was 87.50%(35/40),which was higher than 62.50%(25/40)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the LVMI level of the observation group was lower than that of the control group,the LVEF level was higher than that of the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of cTnI and NT-proBNP in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of TNF-α,IL-6 and hs-CRP in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Sacubitril/Valsartan combined with Metoprolol in the treatment of the CHF patients can improve the total effective rates,improve the levels of cardiac function indicators,and reduce the levels of serological indexes and inflammatory indexes.Moreover,it is superior to single Metoprolol treatment.
NETL
NSTL
万方数据
维普
